KR880002507A - 페닐퀴놀린 카복실산의 동결건조 약제 조성물 - Google Patents
페닐퀴놀린 카복실산의 동결건조 약제 조성물 Download PDFInfo
- Publication number
- KR880002507A KR880002507A KR870009364A KR870009364A KR880002507A KR 880002507 A KR880002507 A KR 880002507A KR 870009364 A KR870009364 A KR 870009364A KR 870009364 A KR870009364 A KR 870009364A KR 880002507 A KR880002507 A KR 880002507A
- Authority
- KR
- South Korea
- Prior art keywords
- salt
- sodium
- acid
- composition
- fluoro
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (12)
- 필수적으로(a)실온에서 mg/ml범위의 수용해도를 갖는 유리산 형태의 약물의 염과(b) 필수적으로 (1) 담즙산 염 및 (2) 수용액으로 재구성시에 8.5 내지 11의 pH를 제공할 수 있는 약제학적으로 무독한 염기 또는 완충제로 이루어진 안정화계의 동결건조 혼합물[여기에서, (a) : (b)(1)의 중량비는 약1:0.1이상이다]로 조성된 비경구 투여용 용액으로 재구성하기에 적합한 분말 약제 조성물.
- 제 1 항에 있어서, (a) : (b)(1)의 중량비가 약1:0.1내지 1:0.8의 범위인 분말 조성물.
- 제 2 항에 있어서, 담즙산 염(b)(1)이 콜산 또는 데스옥시콜산인 분말 조성물.
- 제 3 항에 있어서, 염기 또는 완충제(b)(2)가 수용액으로 재구성시에 약9의 pH를 제공하기에 충분한 글리신 또는 수산화나트륨인 분말 조성물.
- 제 4 항에 있어서, 약물이 페닐퀴놀린카복실산의 나트륨 또는 칼륨 염인 분말 조성물.
- 제 5 항에 있어서, 페닐퀴놀린 카복실산 염이 6-플루오로-2-(2′-플루오로-1′-비페닐-4-일)-3-메틸-4-퀴놀린-카복실산, 나트륨염 또는 2-(1,15-페닐-4-일)-5-클로로-3-메틸-4-퀴놀린카복실산, 나트륨 염인 분말 조성물.
- 필수적으로 (a)1중량부의 6-플루오로-2-(2′-플루오로-1′-비페닐-4-일)-3-메틸-4-퀴놀린카복실산, 나트륨 염과 (b)필수적으로 (1)약 0.1내지 0.8중량부의 나트륨 콜레이트 및 (2) 수용액으로 재구성시에 약9의 pH를 제공하기에 충분한 글리신으로 이루어진 안정화계의 동결건조 혼합물로 구성된 비경구 투여용 용액으로 재구성하기에 적합한 분말 약제 조성물.
- 실온에서 mg/ml범위의 수용해도를 갖는 유리산 형태의 약물의 염1중량부의 수용액, 약물 1부당 약 0.1중량부 이상의 담즙산 염 및 약 8.5내지 11범위의 pH를 제공하기에 충분한 양의 약제학적으로 무독한 염기 또는 완충제로 이루어진 안정한 주사용 약제 조성물.
- 제 8 항에 있어서, 담즙산 염이 약물 1부당 약0.1내지 0.8중량부의 농도로 존재하는 나트륨 콜레이트 또는 나트륨 데스옥시콜레이트 주사용 조성물.
- 제 9 항에 있어서, 염기 또는 완충제가 pH 약9를 제공하기에 충분한 양의 글리신 또는 수산화 나트륨인 주사용 조성물.
- 제10항에 있어서, 약물이 페닐퀴놀린 카복실산의 나트륨 또는 칼륨 염인 주사용 조성물.
- 제11항에 있어서, 페닐퀴놀린 카복실산 염이 6-플루오로-2-(2′-플루오로-1′-비페닐-4-일)-3-메틸-4-퀴놀린카복실 산, 나트륨 염 또는 2-(1,1′-비페닐-4-일)-5-클로로-3-메틸-4-퀴놀린카복실산, 나트륨 염인 주사용 조성물.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90125486A | 1986-08-28 | 1986-08-28 | |
US901,254 | 1986-08-28 | ||
US60203 | 1987-06-10 | ||
US07/060,203 US4889862A (en) | 1986-08-28 | 1987-06-10 | Freeze-dried pharmaceutical compositions of phenylquinoline carboxylic acids |
US901254 | 1987-06-10 | ||
US060,203 | 1987-06-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR880002507A true KR880002507A (ko) | 1988-05-09 |
KR950006218B1 KR950006218B1 (ko) | 1995-06-12 |
Family
ID=26739681
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019870009364A KR950006218B1 (ko) | 1986-08-28 | 1987-08-27 | 페닐퀴놀린 카복실산의 동결건조 약제 조성물 |
Country Status (17)
Country | Link |
---|---|
US (1) | US4889862A (ko) |
EP (1) | EP0261426B1 (ko) |
JP (1) | JP2629005B2 (ko) |
KR (1) | KR950006218B1 (ko) |
AU (1) | AU602715B2 (ko) |
CA (1) | CA1312824C (ko) |
DE (1) | DE3782480T2 (ko) |
DK (1) | DK168655B1 (ko) |
ES (1) | ES2052530T3 (ko) |
FI (1) | FI90824C (ko) |
GR (1) | GR3006608T3 (ko) |
HU (1) | HU199289B (ko) |
IE (1) | IE60490B1 (ko) |
IL (1) | IL83662A (ko) |
NO (1) | NO873626L (ko) |
NZ (1) | NZ221574A (ko) |
PT (1) | PT85612B (ko) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4861783A (en) * | 1988-04-26 | 1989-08-29 | E. I. Du Pont De Nemours And Company | 4-quinoline carboxylic acid derivatives useful for treating skin and muco-epithelial diseases |
HU206975B (en) * | 1991-03-14 | 1993-03-01 | Reanal Finomvegyszergyar | Process for producing granulation and veterinary composition comprising water-soluble flumequine complex |
DK1016409T3 (da) * | 1997-02-05 | 2004-09-20 | Kirin Brewery | Lyofiliseret sammensætning omfattende glycosphingolipider |
US6417167B1 (en) | 1997-02-05 | 2002-07-09 | Kirin Beer Kabushiki Kaisha | Lyophilized compositions containing shingoglycolipid and process for preparing them |
TWI232102B (en) | 2001-07-17 | 2005-05-11 | Shionogi & Co | A pharmaceutical formulation for injection |
US20060008529A1 (en) * | 2004-07-12 | 2006-01-12 | Meyerhoff Mark E | Use of additive sites to control nitric oxide release from nitric oxide donors contained within polymers |
US20080241208A1 (en) * | 2005-06-30 | 2008-10-02 | Charles Shanley | Methods, Compositions and Devices For Promoting Anglogenesis |
WO2007064895A2 (en) * | 2005-12-02 | 2007-06-07 | The Regents Of The University Of Michigan | Polymer compositions, coatings and devices, and methods of making and using the same |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US468299A (en) * | 1892-02-02 | John atkinson | ||
DE433646C (de) * | 1923-09-15 | 1926-09-09 | Chem Fab Vorm E Schering | Verfahren zur Herstellung in Wasser leicht loeslicher Derivate von Carbonsaeuren derChinolin- und Pyridinreihe |
US3681495A (en) * | 1969-08-25 | 1972-08-01 | American Home Prod | Freeze dried echothiophate iodide compositions |
US4036954A (en) * | 1973-11-02 | 1977-07-19 | Yamanouchi Pharmaceutical Co., Ltd. | Stable prostaglandin E group-containing formulation |
JPS5071816A (ko) * | 1973-11-02 | 1975-06-14 | ||
AT356278B (de) * | 1976-07-12 | 1980-04-25 | Hoffmann La Roche | Verfahren zur herstellung von injektions- loesungen |
JPS5976017A (ja) * | 1983-01-20 | 1984-04-28 | Yamanouchi Pharmaceut Co Ltd | 安定なプロスタグランジンe類製剤の製法 |
US4680299A (en) * | 1984-04-30 | 1987-07-14 | E.I. Du Pont De Nemours And Company | 2-phenyl-4-quinolinecarboxylic acids and pharmaceutical compositions thereof |
EP0133244B1 (en) * | 1983-07-22 | 1990-12-05 | E.I. Du Pont De Nemours And Company | Phenylquinolinecarboxylic acids and derivatives as antitumor agents |
DE3329952A1 (de) * | 1983-08-19 | 1985-02-28 | Behringwerke Ag, 3550 Marburg | Verfahren zur verringerung einer truebung in kontrollseren |
EP0179583A1 (en) * | 1984-10-04 | 1986-04-30 | Merck & Co. Inc. | A system for enhancing the water dissolution rate and solubility of poorly soluble drugs |
-
1987
- 1987-06-10 US US07/060,203 patent/US4889862A/en not_active Expired - Lifetime
- 1987-08-18 CA CA000544796A patent/CA1312824C/en not_active Expired - Fee Related
- 1987-08-26 EP EP87112367A patent/EP0261426B1/en not_active Expired - Lifetime
- 1987-08-26 ES ES87112367T patent/ES2052530T3/es not_active Expired - Lifetime
- 1987-08-26 DE DE8787112367T patent/DE3782480T2/de not_active Expired - Fee Related
- 1987-08-26 FI FI873701A patent/FI90824C/fi not_active IP Right Cessation
- 1987-08-26 NZ NZ221574A patent/NZ221574A/xx unknown
- 1987-08-27 JP JP62211503A patent/JP2629005B2/ja not_active Expired - Lifetime
- 1987-08-27 HU HU873780A patent/HU199289B/hu not_active IP Right Cessation
- 1987-08-27 DK DK447887A patent/DK168655B1/da not_active IP Right Cessation
- 1987-08-27 IE IE229087A patent/IE60490B1/en not_active IP Right Cessation
- 1987-08-27 PT PT85612A patent/PT85612B/pt not_active IP Right Cessation
- 1987-08-27 NO NO873626A patent/NO873626L/no unknown
- 1987-08-27 AU AU77622/87A patent/AU602715B2/en not_active Ceased
- 1987-08-27 KR KR1019870009364A patent/KR950006218B1/ko not_active IP Right Cessation
- 1987-08-27 IL IL83662A patent/IL83662A/xx unknown
-
1992
- 1992-12-21 GR GR920403016T patent/GR3006608T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
DE3782480T2 (de) | 1993-04-08 |
NO873626D0 (no) | 1987-08-27 |
EP0261426A1 (en) | 1988-03-30 |
JPS63115816A (ja) | 1988-05-20 |
AU7762287A (en) | 1988-03-03 |
FI873701A (fi) | 1988-02-29 |
AU602715B2 (en) | 1990-10-25 |
GR3006608T3 (ko) | 1993-06-30 |
IE872290L (en) | 1988-02-28 |
PT85612B (pt) | 1990-05-31 |
IE60490B1 (en) | 1994-07-27 |
IL83662A0 (en) | 1988-01-31 |
DE3782480D1 (de) | 1992-12-10 |
CA1312824C (en) | 1993-01-19 |
FI90824C (fi) | 1994-04-11 |
ES2052530T3 (es) | 1994-07-16 |
IL83662A (en) | 1991-09-16 |
US4889862A (en) | 1989-12-26 |
HUT45398A (en) | 1988-07-28 |
HU199289B (en) | 1990-02-28 |
FI873701A0 (fi) | 1987-08-26 |
FI90824B (fi) | 1993-12-31 |
PT85612A (en) | 1987-09-01 |
KR950006218B1 (ko) | 1995-06-12 |
DK447887D0 (da) | 1987-08-27 |
NZ221574A (en) | 1989-11-28 |
DK447887A (da) | 1988-02-29 |
EP0261426B1 (en) | 1992-11-04 |
NO873626L (no) | 1988-02-29 |
JP2629005B2 (ja) | 1997-07-09 |
DK168655B1 (da) | 1994-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Holmgren et al. | Reversal of cyclic AMP-mediated intestinal secretion in mice by chlorpromazine | |
KR850007378A (ko) | 인터로이킨-2의 안정화 조성물의 제조방법 | |
ATE271863T1 (de) | Schilddrüsenhormone enthaltende stabilisierte arzneimittel und verfahren | |
KR970706017A (ko) | 안정한 알파 인터페론 수용액 제형(Stable, aqueous alfainterfer on solution for mulations) | |
KR890015745A (ko) | 수용액으로 존재하는 피록시캄의 제약 조성물 및 그의 제조방법 | |
KR970061270A (ko) | 히토성장호르몬을 함유하는 의약제제 | |
KR870010078A (ko) | 신규의 아미노산 유도체 및 그의 제조방법 | |
KR880002507A (ko) | 페닐퀴놀린 카복실산의 동결건조 약제 조성물 | |
KR830003478A (ko) | 6-N-프로필-8α-메톡시메틸 또는 메틸메르캅토메틸 에르골린 유도체의 제조방법 | |
JPS6416724A (en) | Stable and injectable vinca dimer salt solution | |
KR830002510A (ko) | 생물학적 활성화합물과 하이드록시알킬 전분으로 구성되는 조성물 | |
CA2618184A1 (en) | Stable buffered, pharmaceutical compositions including motilin-like peptides | |
YU86792A (sh) | Rastvor sparfloksacina, njegovo dobijanje i so sparfloksacina kao komponenta rastvora | |
KR860006982A (ko) | 안정한 감마 인터페론 제형의 제조방법 | |
US4061744A (en) | Stable preparation of water-soluble salts of dehydroepiandrosterone sulfate for parenteral administration | |
KR900700098A (ko) | 발기부전의 치료겸 진단용 플라복세이트 및 그 유도체 | |
US4963529A (en) | Stable growth hormone releasing factor preparation | |
KR840002657A (ko) | 인터페론 조성물의 제조방법 | |
US4235900A (en) | Cephradine compositions | |
US2944940A (en) | Adrenocorticotrophin and zinc composition | |
US4600583A (en) | Pharmaceutical compositions | |
EP0397147A3 (en) | Stable solutions of rebeccamycin analog and preparation thereof | |
KR900017581A (ko) | α-아미노보론산 유도체를 함유하는 펩티드-약제 조성물 | |
BR9907166A (pt) | Composição farmacêutica e processo para estabilizar um composto possuindo um grupo éster opcional e um grupo à base de amidina | |
GB1499420A (en) | Ergot peptide alkaloids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
G160 | Decision to publish patent application | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 19980319 Year of fee payment: 4 |
|
LAPS | Lapse due to unpaid annual fee |